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I 
ABSTRACT 
Background. N6-Isopentenyladenosine (iPA) is a member of the cytokinins, a 
family of plant hormones that regulate plant cell growth and differentiation. iPA is 
present in mammalian cells in a free form, as a mononucleotide in the cytoplasm, 
or in a tRNA-bound form. Kinetin Riboside (KR) is devoid of cyclin-dependent 
kinase inhibitory activity and displayed potent antiproliferative activity against 
various human cancer cell lines and induced apoptosis in human myeloid leukemia 
cells. Earlier research has demonstrated that KR antiproliferative and apoptogenic 
activities are antagonized by pharmacological inhibitors of adenosine kinase 
(ADK), suggesting that KR bioactivation through metabolic conversion into the 
nucleotide form is essential for KR cytotoxicity. 
Aims. Apoptotic mechanism of iPA and KR led us to study in details the dose-
dependent cell cycle arrest and apoptogenic effect of iPA and KR on MCF-7 breast 
and HCT-15 colon cell lines. On the other hand, cell cycle progression or apoptosis 
can be affected by activation of cell cycle checkpoints in response to DNA damage. 
We have also studied the interaction of iPA with DNA& BSA as a complementary 
information related to iPA antiproliferative activity.  
Methods. Human breast cancer MCF-7 and HCT-15 colon cencer cells were 
supplied from ATCC. Growth activity of iPA and KR in vitro was evaluated by  the 
Sulforhodamine B (SRB) assay. Apoptosis and cell cycle profile were assessed by 
flow cytometry. To explore the structural changes of macromoleules on addition of 
ligands, UV–vis absorbance spectra of macromoleules were measured at different 
concentrations of ligands.  
Results. We have calculated an IC50 of 12.2 μmol/L for  iPA and IC50 of 15 μmol/L 
for  KR against MCF-7 and same IC50 of 2.5 μmol/L for  both iPA and KR against 
HCT-15. The cell morphology of treated cells was affected by iPA and KR 
treatment and loss of adhesion, rounding, cell shrinkage and detachment from the 
substratum. The MCF-7 cell cycle analysis by flow cytometry showed that there 
was a prominent increase in the amount of sub-G1/G0 phase by iPA treatment. At  
the concentration of 5 µM, KR led to decrease in the percentage of cells in G0/ G1 
phase, which and increase percentage of cells in S and G2/M phase.  Our result 
from structural analysis showed interaction of iPA with DNA and the binding 
constant value KiPA–DNA=4.4 x 10
3 M-1 together with the shift of UV-vis absorbance 
suggest that iPA interacts at DNA surface. The BSA binding studies  showed that 
iPA is located along the polypeptide chains with overall affinity constant of KiPA-
BSA=4.9 x 10
4 M-1 and these spectral changes were caused by compound–BSA 
complex formation, in which compound iPA was strongly bound at the hydrophobic 
positions of the BSA supported by the hydrophobic interaction. 
Conclusion. We concluded that the iPA and KR have cytotoxic effect on human 
MCF-7 and HCT-15 cells with loss of adhesion, rounding, cell shrinkage and 
detachment from the substratum in treated cells. Cell cycle analysis showed an 
indication of the inhibition of cell growth through a mechanism of apoptosis. Our 
result from structural analysis showed interaction of iPA with DNA suggest that iPA 
interacts at DNA surface and research is required in order to demonstrate that this 
surface-binding effect may be related to DNA damage in MCF-7 cells. 
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SIMBOLS LIST 
 
AMP                                     Adenosine monophosphate  
APIPT                                   Adenosine phosphate-isopentenyltransferase  
BA                                        N6-benzyladenine  
BAR                                      N6-benzyladenosine  
BSA                                      Bovine Serum Albumin 
CK                                        Cytokinin 
CKs                                      Cytokinins  
CKr                                       Cytokinin ribosides 
cZ                                         cis-Zeatin 
DMAPP                                 Dimethylallyl diphosphate 
DMEM                                   Dulbecco's Modified Eagle Medium 
DMSO                                   Dimethylsulfoxide 
FACS                                    Fluorescence-activated cell sorting  
FBS                                      Fetal Bovin Serum 
FCM                                      Flow cytometry  
FPPS                                    Farnesyl diphosphate synthesis      
HBA                                      HydroxyBenzylAdenine 
HBAR                                    N6-HydroxybenzylAdenosine 
HepG2                                   Hepto Cellular Carcinoma Cell Line  
HMBDP                                 Hydroxymethylbutenyl diphosphate 
HSA                                      Human Serum Albumin  
iPA                                        N6-(Δ2-isopentenyl)adenosine 
iPAMP                                   Isopentenyladenosine-5'-monophosphate  
IPT                                        Isopentenyl transferase 
IPCKs                                    Isoprenoid cytokinins 
Kinetin                                   N6-furfuryladenine 
KR                                        Kinetin Riboside 
MEP                                      Methylerythritol phosphate  
N6-iA                                      N6-(Δ2-isopentenyl) adenine  
PBS                                      Phosphate buffer saline 
PI                                          Propidium Iodide 
TBE                                       Tris-boratel/EDTA 
tZ                                          trans-zeatin 
TPA                                       Tetradecanoylphorbol-13-acetate  
tRNA-IPT                               tRNA-isopentenyltransferase    
VHL                                       Von Hippel-Lindau  
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1. INTRODUCTION 
 
1.1. Cytokinins (CKs): Biological role and function  
CKs were discovered during the 1950s as substances able to induce the division of 
plant cells. They are a class of plant hormones that play various roles in many 
aspects of plant and development, including apical dominance, the formation and 
activity of shoot stems, leaf senescence, nutrient mobilization, seed germination, 
root growth, and stress responses. Generally natural CKs (Figure 1.1) are N6-
substituted adenine derivatives and generally the substitution at  position N6 
consists of an isoprenoid or an aromatic group [1]. 
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Figure 1.1. Structure of naturally occurring cytokinin and cytokinin riboside  
 
kinetin (Figure 1.2) was the first and the best-known of CKs discovered as a 
degradation product of DNA and was shown to be able to promote cell division in 
plants [2]. The native kinetin was identified in plant root nodules of Casuarina 
equisetifolia  [19] and isolated for the first time in 1950 [1] from autoclaved herring 
sperm  DNA. 
 
 
Figure 1.2. Chemical structure of Kinetin 
 
Since then, a large number of biochemical, physiological and genetic studies have 
focused on elucidating the diverse roles of CKs  in plant growth  and development 
[3]. Both isoprenoid and aromatic CKs are naturally occurring, with the former more 
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frequently found in plants and in greater abundance than the latter. Common 
natural isoprenoid CKs are N6-(Δ2-isopentenyl) adenine (N6-iA), trans-Zeatin (tZ) 
and the related stereoisomer cis-Zeatin (cZ) (Figure 1.3). Among them, the major 
derivatives generally are tZ and N6-iA as well as their sugar conjugates, but there is 
a great variation depending on plant species, tissue, and developmental stage [4].  
Figure 1.3. Chemical structure of tZ, cZ, and N6-iA 
 
Aromatic CKs, N6-benzyladenine (BA) and the three isomeric 
Hydroxybenzyladenine (HBA, topolins)  (Figure 1.4) were identified in several plant 
species including poplar and Arabidopsis [5-7] but it is not yet clear whether they 
are ubiquitous in plants. 
 
Figure 1.4. Chemical structure of Aromatic CKs, BA and the three isomeric HBA. 
 
Usually, for all natural CK nucleobases the corresponding nucleosides, 
nucleotides, and glycosides (Figure 1.5) have been isolated [4]. Glycosylation of 
CK has been observed at the N3, N7, and N9 position of the purine moiety as N-
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glycosides, and at the hydroxyl group of the side chains of tZ, cZ, and 
dihydrozeatin  as O-glucosides or O-xylosides (Figure 1.5). O-glycosylation is 
reversible and the deglycosylation is catalyzed by a β-glucosidase. On the 
contrary, N-glycoconjugates are not efficiently cleaved by  β-glucosidase [8] and  
N-glycosylation results  in a practically irreversible process. The physiological 
consequences of the differences in stability of N-glycosides and O-glycosides are 
not fully understood to date. However, it has been suggested that the readily 
cleaved O-glycosides represent inactive, stable storage forms of CKs [4].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. CK conjugates with sugars, sugar phosphates, and others. O-
Glycosylation of side chain (colored in blue) is catalyzed by zeatin O-
glucosyltransferase or O-xylosyltransferase. N-glucosylation of adenine moiety 
(colored in red) is catalyzed by cytokinin N-glucosyltransferase. 
 
1.2. Biosynthesis of CK and CKr  
1.2.1. Iosprenoid cytokinins (IPCKs)  
CK ribosides and their  phosphates predominantly represent the primary products 
of  CK biosynthesis and the concomitant occurrence of CK and  the corresponding 
nucleosides and nucleotides in plant tissues suggests that important metabolic 
steps are shared with the purine metabolic pathway, i.e., salvage pathway [3] thus, 
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the metabolic  flow from CK nucleotides to the active nucleobases is probably not 
unidirectional but circular (Figure 1.6).  
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Figure 1.6. Current model of IPCKs biosynthesis pathways in Arabidopsis. 
Isoprenoid side chains of N6-iA and tZ predominantly originate from the MEP 
pathway, whereas a large fraction of the cZ side chain is derived from the MVA 
pathway (green arrows).  
 
The first step in the isoprenoid CK biosynthesis [4] is N-prenylation of adenosine 5'-
phosphates (AMP,ADP, or ATP) at the N6-terminus with dimethylallyl diphosphate 
(DMAPP) or hydroxymethylbutenyl diphosphate (HMBDP); this reaction is 
catalyzed by adenosine phosphate-isopentenyltransferase (APIPT) (Figure 1.6). 
CKs may derive from tRNA degradation as well  and shortly after the discovery of 
CKs, it was assumed that tRNA is a major source of CKs because isoprenoid CKs 
were identified in the hydrolysates of tRNAs [9-11]. Thus, tRNA prenylation could 
contribute, at least to some extent, to CK production. Early calculations of turnover 
rates of tRNA led to the conclusion that tRNA degradation was not a major 
pathway of CKs synthesis [12]. 
 
1.2.2. Aromatic cytokinins 
BA (Figure 1.7) has been long considered an artificial CK until this compound was 
isolated from a CK-autotrophic cell culture of anise, Pimpinella anisum L. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Chemical structure of BAR 
 
Additional compounds structurally related to BA and BAR,  are the three isomeric 
HBA and HBAR isolated from leaves of Poplus robusta and N6-(o-hydroxybenzyl)-
2-methylthio-9-β-D-glucofuranosyladenine isolated from fruits of Zantedeschia 
aethiopica robusta [5]. Despite the fact that BA is  one of the most effective and 
affordable CKs and has been widely used in plant biotechnology for several 
decades CK research has typically been focused on the isoprenoid class of CKs, 
typified by zeatin, dihydrozeatin and  N6-iA. The biosynthesis and degradation 
pathways of aromatic CKs remain to be elucidated, although the mechanisms of 
glycosylation and of their interaction with the cellular signaling system appear to be 
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shared with isoprenoid CKs. Apparently, the enzymes and receptors involved 
recognize members of both groups [13,14].  Indirect evidences on the metabolism 
of BA [and possibly BAR] seems to indicate that the HBA could be the result of the 
action of CYP735A or some other P450s on BAR or BA[15]. 
 
1.2.3. Kinetin and Kinetin Riboside (KR) 
A recent review describes in details the mulptiple biological activities of kinetin [16]. 
Kinetin has been the first and the best-known CK, isolated for the first time in 1950 
[1] from autoclaved herring sperm DNA [2]. For a long time, Kinetin was recognized 
as a unnatural synthetic product and  was found in commercially available DNA, in 
freshly extracted cellular DNA from human cells, in plant cell extracts and human 
urine [17,18]. The native kinetin was identified in plant root nodules of Casuarina 
equisetifolia  [19]. Recently Kinetin free base and its riboside (KR) (Figure 1.8) has 
been detected in the endosperm liquid of fresh young coconut fruits [20], at 
concentrations of 0.31 and 0.33 nM, respectively [21]. 
 
Figure 1.8. Chemical structure of K and KR 
 
These findings contribute strongly to answer the question concerning the origin of 
kinetin and other CKs (Figure 1.9). It has been shown that the cells of legume 
nodules contain catalytic amounts of iron, which is required for Fenton reaction and 
formation of hydroxyl radical. The highly reactive oxygen species (ROS) cause 
degradation of cellular component in nodule extracts. The high yield of Fe-
catalyzed Harber-Weiss reaction of deoxyribose damage sustained in vitro by the 
cytosol of bean and cowpea nodules during senescence suggests their potential to 
generate •OH. These data strongly support the hypothesis that CKs can be 
recognized as the products of the oxidative metabolism of the cell [22,23]. The 
proposed mechanism of kinetin formation in DNA in vivo starts with the hydroxyl 
radical oxidation of the deoxyribose residue at the carbon 5' to  yield furfural. This  
Introduction 
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newly formed aldehyde subsequently reacts with the amino group of adenine to 
form the Schiff base followed by intramolecular rearrangement, which can yield K 
formation in vivo (Figure 1.9) [24].  
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Figure 1.9. Scheme of synthesis of kinetin and KR. Furfural as a product of DNA 
oxidation product reacts with ribo or deoxyadenosine. 
 
 
1.3. Occurrence of iPA and Kinetin and KR in mammalians 
As stated in Section 1.2.3. there are good evidences that Kinetin and KR are 
formed in vivo in mammalians as an important component of a new salvage 
pathway of hydroxyl radical constituting a ‘free radical sink’. By this mechanism, the 
cell can find a way to  respond to oxidative stress, inducing defence mechanisms of 
maintenance and repair [24]. According to this hypothesis, KR is formed from 
adenosine to neutralize the harmful properties of hydroxyl radical reaction 
products, such as furfural that is formed by degradation of sugar residues in DNA 
and is one of the major routes of cellular damage in addition to the other 
modifications of nucleic acid bases [25]. In conclusion, although KR is found in 
mammalians, the product represents an artefact of DNA oxidative stress. 
iPA (Figure 1.10) has been  found in tRNA from a wide variety of eukaryotic and 
prokaryotic cells [26]. 
 
N
NN
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O
OHOH
HH
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HO
 
 
 
Figure 1.10. Chemical structure of iPA 
 
The modified base  is derived from 3-methyl-2-buten-1-yl pyrophosphate, an 
intermediate in cellular isoprenoid biosynthesis. The enzyme that catalyzes the first 
reaction is Δ2-isopentenyl pyrophosphate: 5'-AMP Δ2-isopentenyltransferase 
commonly referred to as isopentenyl transferase (IPT) and is the enzyme central to 
all isoprenoid CKs biosynthesis [27]. IPT constitute a family of enzymes that are 
conserved from micro organisms to mammals and are involved in post 
transcriptional modification of tRNA, that, in the case of iPA, consists in the addition 
of  the isopentenyl chain to adenosine of the residue 37 of tRNA [28]. iPA is found 
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adjacent to the 3’ end of the anticodon of tRNAs. This modified nucleoside appears 
only in tRNAs that bind to codons containing uridine as the first base (Figure 1.11).  
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Figure 1.11. Schematic diagram of the IPT reaction. The acceptor substrate is 
adenosine residue of tRNA in tRNA–IPT.  
 
In bacteria, isopentenylated tRNAs have been implicated in the regulation of 
aromatic acid uptake [29] and aerobiosis [30], whereas the precise role of the 
modified nucleotide in tRNA metabolism of eukaryotes is unknown. In general, all 
of RNA modifications are essential in maintaining the correct reading frame of the 
translational machinery, thus improving fidelity and efficiency of protein synthesis 
and avoiding errors that could be detrimental for cells [31]. In this respect, it has 
also been  demonstrated that tRNA containing  iPA binds more efficiently the 
ribosome than the unmodified analogues. Therefore the loss of modified nucleotide 
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from the tRNA can produce pleiotropic effects on accuracy of protein synthesis 
leading to altered cell proliferation and differentiation [32]. Starting from the 
consideration that isoprenylated proteins may  regulate DNA synthesis and the 
level of the isoprenylated protein would be low in cells expressing reduced rates of 
DNA replication It was demonstrated that a 26-kDa protein was present in growing 
Chinese hamster ovary cells [33]   Regenerating liver tissue also exhibited elevated 
levels of iA26.  
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Figure 1.12.  Biosynthesis of iPA in plants. AMP and DMAPP  are converted in 
iPAMP and iPA. IPT is the key regulatory en1zyme of the biosynthesis. 
 
Thus, the expression of PA26 correlates with cellular proliferation and growth. It 
was proposed that iPA contains N6-iP moieties and mediates isoprenoid regulation 
of DNA synthesis, thus affecting  cell proliferation and differentiation in plants and 
animals. The cellular level of free iPA was not decreased in defective yeast strains 
possessing mutations that result in severely reduced amounts of isopentenylated 
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tRNAs. This latter result indicates that free iPA may be derived via a synthetic 
pathway independent of isopentenylated tRNA degradation.  Free, non-tRNA-
associated iPA has been observed in yeasts [34] and the cellular level of free iPA 
was not decreased in defective yeast strains possessing mutations that result in 
severely reduced amounts of isopentenylated tRNAs. This latter result indicates 
that free iPA may be derived via a synthetic pathway independent of 
isopentenylated tRNA degradation. iPA is formed from adenosine monophosphate 
(AMP) into isopentenyladenosine-5'-monophosphate (iPAMP) and following 
phosphate hydrolysis (Figure 1.12).  The enzyme that catalyzes the first reaction is 
Δ2-isopentenyl pyrophosphate: 5'-AMP Δ2-isopentenyltransferase commonly 
referred to as IPT and is the  enzyme central to all isoprenoid CKs biosynthesis 
[35]. 
 
1.4 Antiproliferation activity of CKr   
Crown gall disease, that is characterized by the development of neoplastic growth 
on the infected plant, affects many dicotyledonous plants and is caused by the soil 
bacterium Agrobacterium tumefaciens [36].  A small region of the Ti plasmid (the 
tmr locus),  thought to be involved in phytohormone metabolism in Agrobacterium 
tumefaciens-transformed plant tissue, was cloned and expressed in Escherichia 
coli [37]. By enzyme assay, the tmr locus was shown to encode IPT, the enzyme 
that catalyzes the first step in CK biosynthesis. This established a connection 
between CKs and induction of  callus, a cluster of differentiated plant cells that are 
immortal and proliferate indefinitely, to re-differentiate into adventitious buds. In this 
respect, plant callus cells are similar to human cancer cells and CKs were 
expected to be able to affect the differentiation in some human cancer cells, 
probably, through a common signal transduction system [38]. Antiproliferative 
activity has been confirmed by a recent report that examined the control of 
differentiation and apoptosis of human myeloid leukemia HL-60 cells by CKs and 
their ribosides CKr [39]. The HL-60 (Human promyelocytic leukemia cells) cell line 
is a leukemic cell line that has been used for laboratory research on how certain 
kinds of blood cells are formed. The cell line was derived from a 36-year-old 
woman with acute promyelocytic leukemia at the National Cancer Institute [40]. 
With this line, spontaneous differentiation to mature granulocytes can be induced 
by compounds such as dimethyl sulfoxide (DMSO), or retinoic acid. Other 
compounds like 1,25-dihydroxyvitamin D, 12-O-tetradecanoylphorbol-13-acetate 
(TPA) and GM-CSF can induce HL-60 to differentiate to monocytic, macrophage-
like and eosinophil phenotypes, respectively. The HL-60 cultured cell line provides 
a continuous source of human cells for studying the molecular events of myeloid 
differentiation and the effects of physiologic, pharmacologic, and virologic elements 
on this process. HL-60 cell model was used to study the effect of DNA 
topoisomerase IIα and IIβ on differentiation and apoptosis of cells [41].  Using HL-
60 cell lines, it has been shown that CKs such as kinetin , BA and N6-iP were very 
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effective in inducing nitroblue tetrazolium reduction and morphological changes of 
the cells into mature granulocytes (Table 1.1). 
 
Table 1.1. Effect of adenine analogue on growth of HL-60 cells 
Cells were cultures with various concentration of analogues for 5 days. 
Means of three separate experiments are shown. The IC50 is the 
concentration of compound required for 50% inhibition of cell growth. 
 
Analogues 
 
 
Growth inhibition 
(IC50 μM) 
Purine 58.4 
1-Methyladenine 1.713 
3-Methyladenine 1.172 
2-Aminopurine 1.341 
Olomoucine 326.8 
Adenine 261 
2,6- Diaminopurine 61.3 
Isopentenyladenine 47.6 
Kinetin 48.8 
6-Benzylaminopurine 67.6 
6-Dimethylaminopurine 47.2 
trans-Zeatin 516 
6-n-Hexylaminopurine 87.5 
6-Anilinopurine 56.3 
6-Methylaminopurine 327 
6-Methoxypurine 744 
 
On the other hand, examining the coirresponding ribosides CKr, these compounds  
were more potent than the corresponding CKs for growth inhibition and apoptosis. 
CKRs greatly reduced the intracellular ATP content and disturbed the mitochondrial 
membrane potential, consequentially impairing  the accumulation of reactive 
oxygen species. The same effect was not observed for CKs When the cells were 
incubated with CKRs in the presence of O2.   scavenger, antioxidant or caspase 
inhibitor, apoptosis was significantly reduced and differentiation was greatly 
enhanced (Table 1.2). 
 
Table 1.2. Effect of adenine analogue on growth of HL-60 cells 
Cells were cultures with various concentration of analogues for 5 days. 
Means of three separate experiments are shown. The IC50 is the 
concentration of compound required for 50% inhibition of cell growth. 
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Analogues 
 
Growth inhibition  
(IC50 μM) 
Adenosine 685 
Deoxyadenosine 662 
Isopentenyladenine 0.972 
Kinetin Riboside 0.981 
Benzylaminopurine riboside 0.706 
2,6-Diaminopurine deoxyriboside 6.23 
 
Above results suggest that both CKs and CKr can induce granulocytic 
differentiation of HL-60 cells, but CKr also induce apoptosis prior to the 
differentiation process. In another study [42], the in vitro induction of apoptosis by 
N6-substituted derivatives of adenine (CKs and analogues) or adenosine (CKr and 
analogues) in HL-60 cells has been investigated. Using reversed phase HPLC/MS 
analysis they demonstrated that both N6-substituted derivatives of adenosine and 
adenine are phosphorylated within cells to the monophosphate level. While N6-
substituted derivatives of  adenosine were phosphorylated by adenosine kinase 
and corresponding mononucleotides were produced in large quantities, N6-
substituted derivatives of adenine were converted into the corresponding 
mononucleotides via the phosphoribosyl transferase pathway, which yielded 50–
100 times lower amounts of the mononucleotides than the adenosine kinase 
pathway. Accordingly, N6-substituted derivatives of adenine were relatively 
inefficient inductors of apoptosis (Figure 1.13). 
 
 
 
Figure 1.13. Effect of N6-substituted derivatives of adenosine or adenine on 
apoptosis induction in HL-60 cells. Cells were treated with N6-substituted 
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derivatives of adenosine or adenine, as indicated. Cells were incubated for 12 h 
(black columns) or 24 h (white columns) and the number of apoptotic nuclei was 
evaluated using fluorescence microscopy. 1-Control (untreated cells), 2-10 μM N6-
benzyladenosine, 3-100 μM N6-cyclopentyladenosine, 4-10 μM N6-
dimethyladenosine, 5-10 μM KR, 6-100 μM N6-(4-hydroxy-3-methyl-2-buten-1-
yl)adenosine, 7-10 μM iPA, 8-100 μM N6-benzyladenine, 9-100 μM N6-
dimethyladenine, 10-100 μM kinetin, 11-100 μM N6-(4-hydroxy-3-methyl-2-buten-1-
yl)adenine, and 12-100 μM N6-iP. The experimental points represent mean values 
from three replicate experiments with standard deviations. 
 
Inhibitors of adenosine kinase, that abrogated the formation of the 
monophosphates from N6-substituted derivatives of adenosine, completely 
prevented cells from going into apoptosis. These results consistently support the 
idea that pro-apoptotic effects of N6-substituted derivatives of adenosine are 
related to their intracellular conversion into corresponding mononucleotides which 
activate apoptosis when accumulated. This accumulation leads to a rapid decrease 
in ATP production and consequently to apoptosis induction. Nevertheless, the 
detailed mechanism is unknown. These results proposed an interesting working 
hypothesis related to a different activity of CKs and their CKr, although this 
difference were limited only to human myeloid leukemia HL-60 cells. Among 
examined CKs and related ribosides  CKr, it has been shown that BAR, KR and 
iPA are more effective than related adenine derivatives BA, K or iPA (Table 1 and 
2).  
  
1.4.1.  iPA Antitumor activiyy in vitro. 
Nearly forty years ago, Gallo and co-workers [43] observed that iPA can exert a 
promoting or inhibitory effect on human cell growth, on the bases of used 
concentration and the cell cycle phase. They reported that iPA is a potent inhibitor 
or a stimulator of the DNA synthesis, since addition of iPA at μM concentration 
produced inhibition. Lower concentrations (0.1-1.0 μM ) had a stimulatory effect. 
Moreover they demonstrated that the addition of iPA at increasing times, after cells 
seeding and proliferation stimulation, determined a decrease of mitotic figures, 
suggesting that iPA effects depend on the phase of cell cycle. It was also 
demonstrated that the effects on DNA synthesis are preceded by the inhibition of 
RNA and protein synthesis. In 1973, Divekar et al. demonstrated that iPA is 
cytotoxic for Sarcoma 180 cells as for the majority of the mammalian cells [44]. It 
was observed that iPA at the concentration of 22 and 100 μM inhibited the growth 
of Sarcoma 180 cells (50% and 100% respectively) acting as a potent inhibitor of 
the uptake of purine and pirimidine nucleosides. Studies performed on the extracts 
of these cells demonstrated that iPA is a substrate for adenosine kinase and it is 
also a weak inhibitor of adenosine deaminase, glucose-6-phosphate-
dehydrogenase and methylase of mammalian tRNAs. The authors suggested that 
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iPA cytotoxicity for these cells might be due to its conversion in 5'-monophosphate, 
that  is  cytotoxic at high intracellular levels, affecting the enzymes involved in 
purine metabolism (Figure 1.14). The ability of CKs to induce apoptosis was 
studied by Meisel et al. [45] in several human cell lines and it was observed that 
iPA was the most active CK, specially with respect to Caco-2 and HL-60 cancer 
lines. As previously reported, CKr such as KR and iPA inhibited growth and 
differentiation of human myeloid leukaemia HL-60 cells, inducing their apoptosis 
[39,42]. Laezza and co-workers [46] demonstrated that iPA in thyroid cell FRTL-5 
influences the cAMP dependent organization of the microfilaments. The same 
authors have later  demonstrated that iPA caused a dose-dependent arrest of G0-
G1 cell phase transition associated with a reduction of cells in S phase [47] . 
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Figure 1.14. iPA cytotoxicity might be due to its conversion in 5'-monophosphate. 
 
It was shown  that iPA is able to inhibit farnesyl diphosphate synthesis (FPPS) and 
to affect protein prenylation. This can explain the arrest of tumour cells proliferation 
in a reversible mode, since the addition of farnesol could reverse the process. This 
effect was not mediated by the adenosine receptors but was due to a direct 
modulation of FPPS enzyme activity as a result of its uptake inside the cells.   
In 2005 Dragani and coworkers showed by a pharmacogenomic approach that the 
human tRNA-isopentenyltransferase (TRIT1) gene could be a candidate lung tumor 
suppressor [48]. tRNA-isopentenyltransferase (tRNA-IPT) catalyses the addition of 
iPA on residue 37 of tRNA molecules that bind codons starting with uridine [28]. In 
the cited  study [48], TRIT1 expression in normal lung parenchyma was compared 
with that in A549 lung cancer cells. Cancer cell lines overexpressing the 
biochemically functional TRIT1 variant were analyzed and, as a result, the TRIT1 
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gene was identified as a potential negative regulator of lung carcinogenesis. The 
results obtained by Laezza et al. [47] suggesting that the capability of iPA of  
inhibiting FPPS could concur to arrest tumour cells proliferations was not confirmed 
by Dragani and co-workers  in another study. The  antiproliferative activity of iPA  in 
9 human epithelial cancer cell line derived from different types of malignant tissue 
was examined [49] and FPPS downregulation in A549 cells was not involved in the 
antiproliferative activity of iPA. Dragani et al.  observed complete suppression of 
clonogenic activity in 8 of the cell lines after exposure to iPA at a concentration of 
10 μM. A clonogenic assay is a microbiology technique for studying the 
effectiveness of specific agents on the survival and proliferation of cells. It is 
frequently used in cancer research laboratories to determine the effect of drugs or 
radiation on proliferating tumor cells [50]. Although this technique can provide 
accurate results, the assay is time-consuming to set up and can only provide data 
on tumor cells that can grow in culture. The word "clonogenic" refers to the fact that 
these cells are clones of one another. The experiment involves as major steps 
plating the cells are in a tissue culture vessel and allowed to grow, production of 
colonies, and tratment of the formed colonies (the colonies produced are fixed, 
stained, and counted). Any type of cell could be used in an experiment, but since 
the goal of these experiments in oncological research is the discovery of more 
effective cancer treatments, human tumor cells are a typical choice. The cells 
either come from prepared cell lines, which have been well-studied and whose 
general characteristics are known, or from a biopsy of a tumor in a patient [51]. The 
cells are put in petri dishes or in plates which contain several circular "wells" and 
counting the cell colonies is usually done under a microscope. Figure 1.15 shows 
A549 colonies in untreated and 10 μM iPA-treated cells for 24, 48 or 72 h and 
maintained thereafter in culture medium alone until the end of the experiment. 
 
 
 
 
 
 
 
 
Figure 1.15. Representative plates showing A549 colonies in untreated and 10 μM 
iPA-treated cells for 24, 48 or 72 h and maintained thereafter in culture medium 
alone until the end of the experiment 
 
In the cited work [49], a complete suppression of clonogenic activity in 8 of the lines 
after exposure to iPA  was observed at a concentration of 10 μM.  Specifically, iPA 
was effective with human lung cancer cell lines NCI-H520 and  NCI-H596, with 
breast cancer cell lines MDA-MB-361 and MCF-7, and  nasal septum squamous 
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cell carcinoma cell line RPMI 2650 (Figure 1.16). Human lung cancer cell lines 
A549 and Calu-3, hepatocellular carcinoma cell line HepG2, and colorectal 
adenocarcinoma cell line HT-29 were also examined (Figure 1.17). Only the cell 
line  HT-29 derived from a colorectal cancer showed a significant but incomplete 
inhibition upon iPA  treatment, with about 70% colony inhibition as compared to 
untreated control cells.  
 
 
Figure 1.16. Representative plates showing colony formation in untreated (top) or 
10 μM iPA-treated (bottom) cancer cell lines of different tissue origins. 
 
The incomplete inhibition of HT-29 cell clonogenic activity might rest in reduced 
intracellular adenosine kinase activity, with a consequent slower or decreased 
formation of intracellular iPA-5'-monophosphate which appears to be the ultimate 
cytotoxic agent [44]. Alternatively, a lower permeability of these cells to iPA, as 
compared to the other cell lines, cannot be excluded. 
 
 
Figure 1.17. Representative plates showing colony formation in untreated (top) or 
10 μM iPA-treated (bottom) cancer cell lines of different tissue origins. Only 
colorectal adenocarcinoma cell line HT-29 growth was not completely inhibited. 
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Differently from the results obtained with the human myeloid leukemia cell line HL-
60 [39], only a modest increase in apoptosis after iPA treatment was revealed in 
epithelial cancer lines [48,49]. Indeed, in lung cancer cells tumor growth 
suppression appears to be mediated by inhibition of cell proliferation due to a block 
of DNA synthesis rather than apoptosis. These findings are consistent with the 
reported iPA-induced inhibition of proliferation of rat thyroid tumour cells [46,47,52]. 
Moreover, iPA is able to cause a pronounced change in the morphology of A549 
cells. This is associated to disorganization of actin fibers in the cytoplasm (Figure 
1.18) and overall results  suggest a stress situation for that cell line under iPA 
exposure.  
 
 
Figure 1.18. Changes in cell morphology and in distribution of actin fibers by iPA 
treatment of A549 cells. (a) Representative microscopic fields of A549 cells stained 
with 10% Giemsa 18 h after treatment with 0, 10 or 100 µM iPA. (b) Untreated (left) 
and 100 µM iPA-treated (right) cells showing fuorescence-labeled actin fibers 
(green) and DAPI nuclear staining (cyan). 
 
In 2009, Laezza e al. studied iPA effects on DLD1 human colon cancer cells [52]. 
iPA suppressed the proliferation of cells through inhibition of DNA synthesis, 
causing a cell cycle arrest that correlated with a decrease in the levels of cyclins  A, 
D1 and E with a concomitant increase in the levels of cyclin-dependent kinase 
inhibitor p21waf and p27kip1.  iPA induced apoptosis through an increase in the 
number of annexin V-positive cells, a downregulation of antiapoptotic products and 
caspase-3 activation. The apoptotic effects of iPA were accompanied by sustained 
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phosphorylation and activation of c-jun N-terminal kinase (JNK) that induced 
phosphorylation of c-jun.  
 
1.4.2. in vitro antitumor activity of KR 
Ony a few, recent reports are available in literature about in vitro antitumor activity 
of KR. In the seminal work by Ishii and coll., it has been reported that kinetin 
riboside together with isopentenyladenosine, and benzylaminopurine riboside were 
more potent than the corresponding N6-substituted purines for growth inhibition 
and apoptosis of human myeloid leukemia HL-60 cells [39]. It has also been 
reported that, at 1.5 and 0.2 μM concentration, kinetin riboside KR shows cytotoxic 
effects on M4 Beu human and B16 murine melanoma cells. At these 
concentrations, cell growth is reduced by 50%, respectively, but there was no effect 
on the growth of mice leukaemia P388. KR is toxic at the dose of 25 mg/kg [53]. 
More recent results have shown that KR induces apoptosis in HeLa and mouse 
melanoma B16F-10 cells [54]. B16F10 mouse melanoma cell line is  an established 
model for metastasis [55-57].  HeLa cell is a cell type in an immortal cell line used 
in scientific research. It is one of the oldest and most commonly used human cell 
lines [58]. The line was derived from cervical cancer cells taken from a patient 
named Henrietta Lacks, who eventually died of her cancer on October 4, 1951. The 
cell line was found to be remarkably durable and prolific as illustrated by its 
contamination of many other cell lines used in research [59]. HeLa cells are termed 
“immortal” in that they can divide an unlimited number of times in a laboratory cell 
culture plate as long as fundamental cell survival conditions are met (i.e. being 
maintained and sustained in a suitable environment). There are many strains of 
HeLa cells as they continue to evolve by being grown in cell cultures, but all HeLa 
cells are descended from the same tumor cells removed from Mrs. Lacks. It has 
been estimated that the total number of HeLa cells that have been propagated in 
cell culture far exceeds the total number of cells that were in Henrietta Lacks' body. 
HeLa cells were used by Jonas Salk to test the first polio vaccine in the 1950's. 
Since that time HeLa cells have been used for "research into cancer, AIDS, the 
effects of radiation and toxic substances, gene mapping, and countless other 
scientific pursuits". According to author Rebecca Skloot, by 2009, "more than 
60,000 scientific articles had been published about research done on HeLa, and 
that number References was increasing steadily at a rate of more than 300 papers 
each month. The apoptotic effect of KR in HeLa and mouse melanoma B16F-10 
cells was explained through disruption of the mitochondrial membrane potential, 
induction of  the release of cytochrome c, and activation of caspase-3. Tumor 
growth in mice was dramatically suppressed by KR. In contrast, human skin 
fibroblast CCL-116 and bovine primary fibroblast cells show resistances to KR and 
no significant changes in Bad, Bcl-XL, and cleaved PARP were observed. 
Reported data suggest that KR selectively induces apoptosis in cancer cells 
through the classical mitochondria dependent apoptosis pathway [54]. More recent 
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results have added information on the mechanism of KR-induced antiproliferation 
and apoptosis of cancer cell lines. It has very recently demonstrated that KR 
induced marked suppression of CCND2 transcription and rapidly suppressed cyclin 
D1 and D2 protein expression in primary myeloma cells and tumor lines, causing 
cell-cycle arrest, tumor cell–selective apoptosis, and inhibition of myeloma growth 
in xenografted mice [60]. In another very recent study, a hypothesis about  the 
cytotoxic effects of  KR was tested. KR effects may involveinterference with DNA 
integrity and cellular energy status leading to stress response gene expression and 
cell cycle arrest. Results obtained from MiaPaCa-2 pancreas carcinoma, A375 
melanoma, and various other human cancer cell lines indicate that massive ATP 
depletion and induction of genotoxic stress occurs rapidly in response to KR 
exposure. This is  followed by early upregulation of HMOX1, CDKN1A, and other 
DNA damage/stress response genes. These data suggest that early induction of 
genotoxicity and energy crisis are causative factors involved in KR cytotoxicity and 
anticancer activity [61] (Table 1.3). 
 
Table 1.3. FAdo anti-proliferative activity against primary human 
skin cells and human melanoma, colon, and pancreas cancer 
cell lines. 
IC50 values of FAdo-induced inhibition of proliferation of human skin cells [primary 
keratinocytes (HEK) and dermal fibroblasts (Hs27)] and melanoma (A375, G361, and 
LOX), colon (HT29 and HCT116), and pancreas (MiaPaCa-2) cancer cell lines were 
determined in proliferation 
 
Cell line 
 
 
 IC50 (FADo, μM) 
G361 1.52 
LOX 0.16 
A375 0.28 
HT29 3.00 
HCT116 0.27 
MiaPaCa-2 6.23 
HEK 0.11 
Hs27 0.18 
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2.  RATIONAL 
2.1 Cancer 
Cancer is a class of diseases in which a cell, or a group of cells display 
uncontrolled growth (division beyond the normal limits), invasion (intrusion on and 
destruction of adjacent tissues), and sometimes metastasis (spread to other 
locations in the body via lymph or blood). These three malignant properties of 
cancers differentiate them from benign tumors, which are self-limited, and do not 
invade or metastasize. Most cancers form a tumor but some, like leukemia, do not. 
The branch of medicine concerned with the study, diagnosis, treatment, and 
prevention of cancer is oncology [62]. Nearly all cancers are caused by 
abnormalities in the genetic material of the transformed cells. These abnormalities 
may be due to the effects of carcinogens, such as tobacco smoke, radiation, 
chemicals, or infectious agents. Other cancer-promoting genetic abnormalities may 
be randomly acquired through errors in DNA replication, or are inherited, and thus 
present in all cells from birth. The heritability of cancers is usually affected by 
complex interactions between carcinogens and the host's genome. New aspects of 
the genetics of cancer pathogenesis, such as DNA methylation, and microRNAs 
are increasingly recognized as important. Genetic abnormalities found in cancer 
typically affect two general classes of genes. Cancer-promoting ''oncogenes'' are 
typically activated in cancer cells, giving those cells new properties, such as 
hyperactive growth and division, protection against programmed cell death, loss of 
respect for normal tissue boundaries, and the ability to become established in 
diverse tissue environments. ''Tumor suppressor genes'' are then inactivated in 
cancer cells, resulting in the loss of normal functions in those cells, such as 
accurate DNA replication, control over the cell cycle, orientation and adhesion 
within tissues, and interaction with protective cells of the immune system (Figure 
2.1) [63-64]. 
 
Figure 2.1. A cancerous cell looks and acts differently from a normal cell (and may 
have molecules on its surface that are different in number or type from those on a 
normal cell). 
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2.2 Chemotherapy 
Chemotherapy is a general term for treatments that use chemical agents (drugs) to 
kill cancer cells. Many different kinds of drugs are used, either alone or in 
combination, to treat different cancers. The specific drug or combination used is 
chosen to best combat the type and extent of cancer present. Chemotherapy drugs 
are given for several reasons: i)To treat cancers that respond well to 
chemotherapy, ii) To decrease the size of tumors for easier and safer removal by 
surgery, iii)To enhance the cancer-killing effectiveness of other treatments, such as 
radiation therapy, iv)In higher dosages, to overcome the resistance of cancer cells, 
v)To control the cancer and enhance the patient's quality of life. Healthy normal 
cells in the body grow and divide in an orderly manner to replace old or damaged 
cells. Cancer cells have lost that capacity and divide out of control. Chemotherapy 
drugs work by interfering with the ability of cancer cells to divide and reproduce 
themselves. Chemotherapy can be delivered by the bloodstream to reach cancer 
cells all over the body, or it can be administered directly to specific cancer sites. 
Each chemotherapy drug works in a different way to prevent cells from growing. 
Often a combination of drugs will be used, with each drug attacking the cancer 
cells in a different way. This decreases the possibility that cancer cells will survive, 
become resistant and continue to grow [65-66]. 
 
2.3 MCF-7 breast cancer  
In 1970, the MCF-7 cell line was derived from a pleural effusion of a patient with 
metastatic breast cancer [67] and was later recognized as the first hormone-
responsive breast cancer cell line [68]. The usefulness of the MCF-7 cell line as an 
investigative tool led to its adoption in laboratories worldwide and several decades 
of use in independent laboratories have facilitated the evolution of distinct MCF-7 
lineages [69]. Documented differences include the ability to undergo DNA 
fragmentation, differential sensitivities to estrogens and anti-estrogens, differential 
expression of estrogen receptors (ER), ER-mRNA, progesterone receptors and 
differences in tumorigenicity and proliferative rates. It has been well established 
that the MCF-7 cell line is a novel tool for the study of breast cancer resistance to 
chemotherapy, because it appears to mirror the heterogeneity of tumor cells in vivo 
[70]. In this respect, it has already been proved that breast cancer cell lines are 
considered as representative models of transformed cells in vivo [71].  In addition 
to retaining their estrogen sensitivity, MCF-7 cells are also sensitive to cytokeratin. 
They are unreceptive to desmin, endothelin, GAP, and vimentin. When grown in 
vitro, the cell line is capable of forming domes and the epithelial like cells grow in 
monolayers. Growth can be inhibited using tumor necrosis factor alpha (TNF 
alpha), and treatment of MCF-7 cancer cells with anti-estrogens can modulate 
insulin-like growth factor finding protein's, which ultimately have the effect of a 
reduction in cell growth. 
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Figure 2.2. Cell shape of MCF-7 breast cancer cell line 
 
2.4 HCT-15 a colorectal cancer cell line 
Colorectal cancer is the second leading cause of cancer death in the United 
States[72]. Despite advances in medical practices and chemotherapeutic protocols, 
survival rates in cases of colorectal cancer have changed little over the last 20 
years. HCT-15 cells have mutant p53. Mutated p53 is often expressed in 
variety of human tumors and contribute to malignant process by loss of tumor 
suppressor function and gain of novel functions that enhance transformed 
properties of cells [73]. Swamy et al [74] reported that celecoxib increases 
nuclear localization of active p53. The treatment of celecoxib in HCT-15 cells 
might involve inhibition of function of mutated p53. 
Figure 2.3. Cell shape of HCT-15 colon cancer cell line 
 
2.5 Binding study of macromolecules 
Macromolecules in the body form noncovalent associations, such as DNA-
protein or protein-protein complexes, that control and regulate numerous 
cellular functions. Understanding how changes in the concentration and 
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conformation of these macromolecules can trigger physiological responses is 
essential for researchers developing drug therapies to treat diseases affected 
by these imbalances.  
 
2.5.1 Drug-DNA interaction  
DNA as carrier of genetic information is a major target for drug interaction [75] 
because of the ability to interfere with transcription (gene expression and protein 
synthesis) and DNA replication [76], a major step in cell growth and division [77]. 
The latter is central for tumorigenesis and pathogenesis [78]. Thanks to the work of 
James Watson, Francis Crick, Linus Pauling, and many other scientists, we now 
know that DNA is a double helix (spiral) molecule, consisting of two complementary 
strands of sugar-phosphate groups with bases attached (Figure 2.4). 
 
 Figure 2.4. Francis Crick was a pre-doctoral student of James Watson. They did 
their research in 1951 at Cambridge University in England. 
 
The sequence of bases (A, G, C, and T) provide all the genetic information needed 
to carry out the cell’s activities. A mutation is a permanent change in the DNA. A 
mutation can arise spontaneously without apparent cause, or in response to 
radiation, ultraviolet light, certain chemicals, or viruses. Some mutations involve the 
substitution of one base pair for another, for example inserting a G-C where there 
should be a T-A pair. In other cases, one or more base pairs can be added to, or 
removed from, the chain. Sometimes huge segments are altered, rearranged, or 
misaligned. Mutations can lead to cell death, to alterations in the way a cell 
functions, or in some cases to cancer. This may be because treatment is difficult, 
there may be no cure, and the disease seems to strike without warning. 
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There are three principally different ways of drug-binding. First, through control of 
transcription factors [79,80] and polymerases [81, 82, 83]. Here, the drugs interact 
with the proteins that bind to DNA. Second, through RNA binding to DNA double 
helices to form nucleic acid triple helical structures or RNA hybridization (sequence 
specific binding) to exposed DNA single strand regions forming DNA-RNA hybrids 
that may interfere with transcriptional activity. Third, small aromatic ligand 
molecules that bind to DNA double helical structures by (i) intercalating between 
stacked base pairs thereby distorting the DNA backbone conformation and 
interfering with DNA-protein interaction or (ii) the minor groove binders. The latter 
cause little distortion of the DNA backbone (Figure 2.5).  Both work through non 
covalent interaction. The small ligand drug approach offers a simple solution. The 
synthesis and screening of synthetic compounds that do not exist in nature, work 
much like pharmacological ligand for cell surface receptors in excitable tissue, and 
appear to be more readily delivered to cellular targets than large RNA or protein 
ligands. The lack of sequence specificity for intercalating molecules, however, does 
not allow to target specific genes, but rather certain cellular states or physiological 
and pathological conditions, like rapid cell growth and division that can be 
selectively suppressed as compared to non growing or slowly growing healthy 
tissue [84-92]. 
 
Figure 2.5. Schematic diagram showing the different binding modes of ligands to 
DNA. 
 
2.5.2 Conformation investigation of Bovine Serum Albumin 
Serum albumins are the major soluble protein constituents of the circulatory system 
and have many physiological functions[93-96]. Binding to albumin is an important 
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factor in the solubilization and transportation of drugs in blood [97-99] and the 
molecules that have higher affinity for serum albumin and show preferential binding 
sites on serum albumin may find important therapeutical applications[100]. The 
most important property of this group of proteins is that they serve as transporters 
for a variety of compounds. BSA (Figure 5.18) has been one of the most 
extensively studied of this group of proteins, particularly because of its structural 
homology with human serum albumin (HSA) [101-103]. Over the past years, 
studies on the interactions between drugs and BSA in aqueous solution have 
attracted intense attentions [104-109]. 
 
 
 
Figure 2.5. Structure of BSA 
 
2.6 Rational of this work 
Studing on cytotoxic effect of antiproliferative agents on human cancer cell lines 
that cause apoptotic morphological changes in cells is very interesting in molecular 
biological chemistry field. The cell cycle analysis by flow cytometry with increase of 
hypoploid DNA is an indication of the inhibition of cell growth through a mechanism 
of apoptosis that has been suggested also for other cell lines [39, 46-47]. On the 
other hand, the connection between DNA damage and apoptosis is supported by a 
large body of literature [110,111] and also plasma protein binding is one major 
determinant of the distribution of chemicals in the body. In vitro, in cell cultures for 
example, media often are supplemented with up to 20% (v/v) serum and in those 
cases the distribution of chemicals can also be determined by protein binding. 
Binding to serum components in the medium can reduce the availability of 
chemicals in cell culture systems, which means that the freely dissolved 
concentrations are lower than the nominal ones. In most cases in vitro potency 
data, used to characterise the biological activity of chemicals, are based on 
nominal concentrations and not on the actual effective freely dissolved 
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concentrations. As consequence binding to serum components in the medium also 
affects potency data obtained with cell cultures. The dependency of in vitro potency 
data upon serum or albumin content of the medium has been shown frequently 
[112-114]. At present work, As a complementary information related to the 
antiproliferative activity, no clear evidence of cytokinines-induced DNA damage 
and protein structural analysis has been demonstrated. 
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3. AIMS 
 
CKs are purine derivatives with potential anticancer activity originally discovered as 
phytohormones that promote cell division, leaf expansion, and callus cell 
redifferentiation, early and recent experimental evidence suggests that naturally 
occurring and synthetic CKs target human cancer cells through anti-proliferative, 
apoptogenic, and differentiation-inducing activities.  
iPA is a member of the CKs, a family of plant hormones that regulate plant cell 
growth and differentiation. iPA is present in mammalian cells in a free form, as a 
mononucleotide in the cytoplasm, or in a tRNA-bound form. On the other hand, KR 
has been shown to exert growth inhibitory effects and also induce apoptosis. It has 
been implicated in the reduction of intracellular ATP level and mitochondrial 
membrane potential and the induction of reactive oxygen species, whereas CK 
protects against mitochondrial disruption and apoptosis in HL-60 cells. In addition, 
treatment with KR leads to cytotoxic effects on mouse, human, and plant tumor 
cells. Thus, iPA and KR appear to have an important role in the induction of cell 
death in different types of cancer cells. 
Therefore, In the present work, we report our results from a  study designed to 
determine the time dose-dependent antiproliferative and cytotoxicity effect of iPA 
and KR against on MCF-7 breast cancer and HCT-15 colon cancer cell lines that 
measured by the SRB assay and other antiproliferation assays.  Also incubation of 
the MCF-7 and HCT-15 cell lines with different concentrations of iPA and KR 
investigated after treatment with significant morphological changes including cell 
rounding and detachment from the substratum. Then dose-dependent cell cycle 
arrest and apoptogenic effect of iPA and KR on cell lines were investigated. As a 
complementary information related to the antiproliferative activity, iPA interaction 
with DNA has been studied analyzing absorbance changes in the UV–vis 
frequency range with the aim to obtain structural information regarding the iPA 
binding mode, apparent binding constant, and the effects of iPA complexation on 
the biopolymer secondary structure. Additionally, we present results obtained from 
the interaction of iPA and  BSA since protein–drug binding greatly influences 
absorption, distribution, metabolism, and excretion properties of typical drugs, 
studies on the protein–drug binding are important for the elucidation of the reaction 
mechanisms, providing a pathway to the pharmacokinetics and pharmacodynamic 
mechanisms of these substances in various tissues. 
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4. MATERIALS AND METHODS 
 
4.1 Chemicals and materials 
iPA and KR dissolved in DMSO was from Sigma company. Trypsin, Trypan Blue, 
antibiotic and antimycotic agent, fetal bovine serum (FBS), SRB, DMSO, and fish 
sperm DNA (fs-DNA), Bovine Serum Albumin, Kinetin Riboside were purchased 
from Sigma Chemical Co. (St. Louis, MO). Chemicals and solvents for iPA 
synthesis were purchased from Sigma-Aldrich Italia (Milan, Italy).  
 
4.2 Chemical synthesis of  iPA 
iPA was prepared following the method described by Robins [115]. Briefly, reaction 
of adenosine with isopentenyl bromide affords iPA in 40% overall yield. An 
alternative procedure required more expensive 6-chloropurine riboside and 
isopentenylamine, but proceded with 82% yield of the final product. 
 
4.3 Cell culture 
Human breast cancer MCF-7 and HCT-15 colon cancer cells were supplied from 
ATCC and were maintained in the standard medium and grown as a monolayer in 
Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS), 2 mM 
glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. Cultures were 
maintained at 37 °C with 5% CO2 in a humidified atmosphere. 
 
4.4 In vitro evaluation of cytotoxic activities by SRB assay 
Growth activity of iPA and KR in vitro were evaluated by  the SRB assay [116-117]. 
iPA and KR stock solution (10 mM in DMSO) was  stored at 4°C and diluted with 
DMEM up to 0.1–1 mM range at room temperature before treatment. The final 
percentage of DMSO in the reaction mixture was less than 1% (v/v). Cancer cells 
(2 x 103 cells/ well) were plated in 96-wells plates and incubated in medium for 24 
hours. Serial dilutions of individual compounds were added. The plates were 
incubated at 37 °C, for 72 hours prior to addition of iPA and KR. The assay was 
terminated by the addition of 50 μL of ice-cold trichloroacetic acid (final 
concentration, 10% TCA) and incubated for 60 min at 4°C. The plates were 
washed five times with distilled water and air-dried. SRB solution (50 µL) at 0.4% 
(w/v) in 1% acetic acid was added to each of the wells, and plates were incubated 
for 30 min at room temperature. The residual dye was removed by washing five 
times with 1% acetic acid. The plates were air-dried or under hood. Bound stain 
was subsequently eluted with 10 mM Trizma base, and the absorbance was read 
on an ELISA plate reader at a wavelength of 540 nm and used as a relative 
measure of viable cell number. The percentage of growth inhibition was calculated 
by using the equation: percentage growth inhibition (1- At/Ac) x 100, where At and 
Ac represent the absorbance in treated and control cultures, respectively. IC50 was 
determined by interpolation from dose–response curves. 
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4.5 In vitro evaluation of cytotoxic activities by MTT assay 
MTT is a simple colorimetric assay, as a test for cell proliferation and survival, has 
been adapted for theVmeasurement of cytotoxicity. This assay involves the ability 
of viable cells to convert a soluble tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide) into a blue formazan endproduct by 
mitochondrial dehydrogenase enzymes. The blue color reaction is used as a 
measure of cell viability. The assay is performed in 96-well plates, and results are 
read on a multiwell spectrophotometer. For this purpose, 2 × 103 cells in 150 μL of 
culture medium were seeded in each well of 96 wells.  The assay was run in 
quadruplicate so that control and dilution values were obtained as the mean values 
of four identical wells. After 24 h incubation at 37°C under a humidified 5% CO2 
containing air atmosphere, the series of drug concentrations were prepared and 
added to each well. After 72 hours incubation 25 μL of 5 mg/ml of MTT (Sigma 
Chemical Co.) in saline was added into each well and incubated for a further 4 
hours at 37°C and then removed and  formazan precipitate. 200 μM of DMSO was 
added to each well for solubilization of precipitated formazan. The absorbance was 
read on an ELISA plate reader at a wavelength of 540 nm and used as a relative 
measure of viable cell number. The percentage of growth inhibition was calculated 
by using the equation: percentage growth inhibition  (1- At/Ac) x 100, where At and 
Ac represent the absorbance in treated and control cultures, respectively. IC50 was 
determined by interpolation from dose–response curves. 
 
4.6 Tryptan blue exclusion test 
The trypan blue exclusion test is used to determine the number of viable cells 
present in a cell suspension. In fact programmed cell death or apoptotic cell death 
was confirmed by trypan blue was analyzed by trypan blue dye (Sigma–Aldrich, 
Germany) on both HCT-15 and MCF-7 cell line. The cell culture plates with 70–
80% confluence were treated with IC50 dose of iPA and KR for 24 h, 48h and 72hr. 
The supernatant medium with floating cells was collected after treatment and 
centrifuged to collect the dead and apoptotic cells. The cell pellet was resuspended 
in serum free media. Equal amounts of cell suspension and trypan blue were mixed 
and this was analyzed under a microscope. The cells which were viable excluded 
the dye and were colorless and the ones whose cell membrane was destroyed 
were turning into blue. If the proportion of colorless cells were more compared to 
the ones that were colored then the death can be characterized as apoptotic. 
 
4.7 Evaluation of cell morphology 
It is now generally accepted that cell death is an important phenomenon, reflected 
by the appearance of numerous publications on the subject every year. For more 
than 150 years, morphological features played the leading role in the description of 
cell death [118]. However, during the past three decades cell death has been 
characterized on the molecular level, which markedly increased our understanding 
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of the morphology [119]. Under inverted microscope, cell shape and its changes 
can be observed clearly. Treated and untreated (control) cells were viewed using 
an inverted phase-contrast microscope model Zeiss and photographed using a 
Nikon camera attached to the microscope. The evaluation of cell morphology 
investigated by the incubation of the cells with different concentrations of iPA and 
KR after 48 h treatment. HCT-15 and MCF-7 cells were plated at about 20,000 
cells/well on chamber-slides (8 wells), were treated with 0, 2.5, 5 and 10M of iPA 
for 48 hours. After rinsing in PBS, cells were either fixed in methanol and stained 
with 10% Giemsa and photographed using a Nikon camera attached to the 
microscope. 
 
4.8 Cell cycle analysis by flowcytometery  
Analysis of a population of cells replication state can be achieved fluorescence 
labelling of the nuclei of cells in suspension and then analyzing the fluorescence 
properties of each cell in the population. Quiescent and G1 cells will one copy of 
DNA and will therefore have 1X fluorescence intensity. Cells in G2/M phase of cell 
cycle will have to copies of DNA and accordingly will have 2X intensity. Since the 
cells in S phase are synthesizing DNA they will have fluorescence values between 
the 1X and 2X populations. The resulting histograms consists of three populations: 
two peaks (G1 and G2/M populations) and the S-phase population. 
Apoptosis and cell cycle profile were assessed by flow cytometry analysis by DNA 
staining with propidium iodide (PI). MCF-7 and HCT-15 cells were plated at a 
density of 5 x 105 cells/well on six-well plates. Cells treated with iPA at different 
concentration of 1, 5 and 10 µM  for 72 hours were harvested, rinsed in PBS, 
suspended in  600µl of PBS containing 1%FBS, fixed by 1.4 ml 80% ethanol and 
stored at -20 °C in fixation buffer. Then the pellets were suspended in 1 ml of 
fluorochromic solution [0.08 mg/ml PI in 1x PBS] at room temperature in the dark 
for 60 min. The DNA content was analyzed by FACScan flow cytometer (Beckman 
Counter, cytomics FC 500) and CellQuest software (Becton Dickinson). The 
population of apoptotic nuclei (subdiploid DNA peak in the DNA fluorescence 
histogram) was expressed as the percentage in the entire population. 
 
4.9  DNA Fragmentation Analysis 
Cells were harvested, washed with ice-cold Phosphate Buffer Salin (PBS), and 
lysed in 50mL lysis buffer (5mM Tris–HCl pH 8.0, 10mM EDTA, and 0.5% Triton X-
100) on ice for 20 min. Then, the cell lysate was centrifuged at 12 000 rpm for 20 
min. The supernatant was treated with RNase A (100 mg/mL) at 378C for 60 min 
and proteinase K (200 mg/mL) at 508C for 120 min. Then, the DNA was extracted 
by phenol/chloroform before loading and analysis by 1.8% agarose gel 
electrophoresis. The gels were run at 50V for 120 min in Tris–borate/EDTA (TBE) 
buffer. Approximately, 20 mL DNA was loaded, stained by ethidium bromide, and 
visualized under UV light. 
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4.10 Clonogenic assays 
Clonogenic assay or colony formation assay is an in vitro cell survival assay base 
on the ability of single cell to grow an colony. The colony is defined to consist of at 
least 50 cells. The assay essentially tests every cell in the population for its ability 
to undergo "unlimited" division. Clonogenic assay is the method of choice to 
determine cell reproductive death after treatment with ionizing radiation, but can 
also be used to determined effectiveness of other cytotoxic agents. Only a fraction 
of seeded cell retains the capacity to product colonies. 
MCF-7 and HCT-15 cells/well were seeded in 6-well tissue culture plates at a 
density of 500-700 cells/well according to the morphology and growth patterns of 
each cell line and were allowed adhere for 24 hours before treatment. The cells 
were treated with different concentration of iPA and KR for 12 days. Triplicate 
samples were used for each treatment. Medium containing the treatment was 
replaced with a drug-free medium after the indicated time points. Plates were 
rinsed in PBS and colonies were methanol-fixed and stained with 10% Giemsa and 
Clones were counted under a light microscope. 
 
4.11 DNA titration experiments 
The absorbance at 260 and 280 nm was recorded, in order to check the protein 
content of DNA solution. DNA (5 mg/ml) was dissolved in distilled water (pH 7) at 
4°C for 24 h with occasional stirring to ensure the formation of a homogeneous 
solution. The final concentration of the DNA solution was determined 
spectrophotometrically at 260 nm using molar extinction coefficient ε260 = 6600 cm
-1 
M-1 (expressed as molarity of phosphate groups). The UV absorbance at 260 nm of 
a diluted solution (1/187.5) of DNA used in our experiments was 0.666 and the final 
concentration of the DNA solution was 12.5 mM in DNA. The appropriate amounts 
of iPA and KR (0.05–12.5 mM) were prepared in distilled water and added 
dropwise to DNA solution in order to attain the desired ligand/DNA molar ratios (r) 
of 1/40, 1/20, 1/10, 1/5, 1/2 and 1 with a final DNA concentration of 6.25 mM. The 
pH of the solutions was adjusted at 7.0 ± 0.2 using NaOH solution. 
 
4.12 BSA binding experiments 
BSA  stock solution 2.5 x 10-5 molL-1 (MW= 68000 g/mol) was prepared  in working 
solution 0.05 molL-1 Tris-HCl buffer Ph=7.4 containing 0.1 mol L-1 NaCl then stored 
at 4° C. The solutions of drugs  1.5 x 10-5- 25 x 10-5 molL-1  were prepared by 
dissolving the drug in working solution 0.05 molL-1 Tris-HCl buffer pH=7.4 
containing 0.1 mol L-1 NaCl. In the final step, drug solution was added dropwise to 
the protein solution with constant stirring to ensure the formation of homogeneous 
solution and to attain the desired drug. The pH of the solution was adjusted to 6.8-
7.4 by the addition of NaOH/NaOD or HCl/DCl (0.1 M). 
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5.  RESULTS 
 
5.1 Antiproliferation evaluation  
5.1.1 Inhibition growth of iPA against MCF-7 
Antiproliferation activity of iPA against human breast cancer MCF-7 cells was 
investigated by SRB assay and results showed that iPA  inhibits the growth of 
MCF-7 in a dose dependent manner with an IC50 value of 12.2 μmol/L. In the 
presence of different concentrations of iPA, the cells were inhibited ranging from 
10% to 90% of viable cells (Figure 5.1A). iPA inhibited the proliferation of MCF-7 
cells in a concentration and time-dependent manner. iPA caused dose dependent 
cell death in MCF-7. From these two data we have calculated an IC50 of 12.2 
μmol/L (Figure 5.1B).  
 
Figure 5.1. (A) Effects of iPA on the proliferation of MCF-7. Dose of 
compound required to inhibit cell growth by 50% compared to untreated cell 
controls. All experiments were carried out in triplicate wells and each 
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experiment was repeated twice. (B) Inhibition growth of of iPA on MCF-7.  
The percentage of growth inhibition was calculated by using the equation: (1- 
At/Ac) x 100, where At and Ac represent the absorbance in treated and control 
cultures, respectively. IC50 was determined by interpolation from dose–response 
curves. 
 
5.1.2 Inhibition growth of iPA against HCT-15   
Treatment with iPA inhibits the growth of human colon cancer HCT-15 cells in a 
dose dependent manner with an IC50 value of 2.5 μmol/L. In the presence of 
different concentrations of iPA, the cells were inhibited ranging from 10% to 90% of 
viable cells (Figure 5.2A). iPA caused dose dependent cell death in HCT-15. From 
these two data we have calculated as IC50 of 2.5 μmol/L (Figure 5.2B). 
 
Figure 5.2. (A) Effects of iPA on the proliferation of HCT-15. Dose of 
compound required to inhibit cell growth by 50% compared to untreated cell 
controls. All experiments were carried out in triplicate wells and each 
experiment was repeated twice. (B) Inhibition growth of of iPA on HCT-15.  
The percentage of growth inhibition was calculated by using the equation: (1- 
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At/Ac) x 100, where At and Ac represent the absorbance in treated and control 
cultures, respectively. IC50 was determined by interpolation from dose–
response curves. 
 
5.1.3 Inhibition growth of KR against MCF-7  
KR was evaluated  for its growth inhibitory effect on MCF-7 breast cancer cell line. 
Therefore the cells were treated with KR at different concentrations, ranging from 1 
µM to 500 µM for 4 days (Figure 5.3.). The results from Figure 5.3. show that 
activity of KR started before first day since there is distance between points in first 
day, since we expected that points should be close to eachothers at first day, so 
decided to reaped the experiment again and read absorbances after hours, not 
after days. So the cells were treated with KR at different concentrations, ranging 
from 1 µM to 100 µM for 86 hours (Figure 5.4) and absorbances at 540 nm were 
read after 6, 12, 28, 52 and 86 hours. 
 
  
 
 
 
Figure 5.3. Antiproliferative effect of KR on MCF-7. Proliferation index was 
evaluated by the SRB assay in cancer cell lines with ranging from 1µM to 500 µM 
for 4 days. The values are the mean of three independent experiments. 
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Figure 5.4. Antiproliferative effect of KR on MCF-7. Proliferation index was 
evaluated by the SRB assay in cancer cell lines with ranging from 1µM to 100 µM 
for 86 hours. absorbances at 540 nm were read after 6, 12, 28, 52, 86 hours.The 
values are the mean of three independent experiments. 
 
The compound concentration causing a 50% cell growth inhibition (IC50) was 
determined by interpolation from dose–response curves. The percentage growth 
inhibition was calculated by comparison of the absorbance of treated versus control 
cells. The antiproliferative effects mediated by KR on the growth of MCF-7 cell 
lines, was monitored for a total of four days. From these two data we have 
calculated as IC50 of 15 μmol/L (Figure 5.5).  
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Figure 5.5. Inhibition growth of of KR on MCF-7.  The percentage of growth 
inhibition was calculated by using the equation: (1- At/Ac) x 100, where At and Ac 
represent the absorbance in treated and control cultures, respectively. IC50 was 
determined by interpolation from dose–response curves. 
 
 
5.1.4 Inhibition growth of KR against HCT-15  
Kinetin riboside was evaluated  for its growth inhibitory effect on HCT-15 colon 
cancer cell line. Therefore the cells were treated with KR at different 
concentrations, ranging from 1 µM to 500 µM for 4 days (Figure 5.6).  
 
 
 
Figure 5.6. Antiproliferative effect of KR on HCT-15. Proliferation index was 
evaluated by the SRB assay in cancer cell lines with ranging from 1µM to 500 µM 
for 4 days. The values are the mean of three independent experiments. 
 
 
In the presence of different concentrations of KR, the cells were inhibited ranging 
from 10% to 90% of viable cells (Figure 5.7). KR inhibited the proliferation of HCT-
15 cells in a concentration and time-dependent manner. KR caused dose 
dependent cell death in HCT-15. From these two data we have calculated as IC50 
of 2.5 μmol/L (Figure 5.7).  
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Figure 5.7. Inhibition growth of of KR on HCT-15.  The percentage of growth 
inhibition was calculated by using the equation: (1- At/Ac) x 100, where At and Ac 
represent the absorbance in treated and control cultures, respectively. IC50 was 
determined by interpolation from dose–response curves. 
 
5.2 Cell shape and morphology study 
Cell death occurs frequently in complex, multicellular, organisms to maintain tissue 
homeostasis. For example, cells die during embryonic development. Also, the 
killing of infected cells by cytolytic effector cells of the immune system is an 
example of cell death in tissue maintenance. It is now generally accepted that cell 
death is an important phenomenon, reflected by the appearance of numerous 
publications on the subject every year. For more than 150 years, morphological 
features played the leading role in the description of cell death. However, during 
the past three decades cell death has been characterized on the molecular level, 
which markedly increased our understanding of the morphology. 
Cell shape and morphology of treated and untreated (control) cells were viewed 
using an inverted phase-contrast microscope model Zeiss and photographed using 
a Nikon camera attached to the microscope. Bellows figures show the incubation of 
the cells with different concentrations of iPA and KR after 72 hours treatment. 
Control group showed regular polygonal shape and cell antennas were short.  The 
cell morphology of treated cells was affected by iPA and KR treatment and loss of 
adhesion, rounding, cell shrinkage and detachment from the substratum (Figure 
5.8, 5.9, 5.10, 5.11). 
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Figure 5.8. Changes in cell morphology and iPA treatment of MCF-7 cells 
 
 
 
Figure 5.9. Changes in cell morphology and iPA treatment of HCT-15 cells 
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Figure 5.10. Changes in cell morphology and KR treatment of HCT-15 cells 
 
 
Figure 5.11. Changes in cell morphology and KR treatment of MCF-7 cells 
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5.3 Cell Cycle Analysis  
5.3.1 Cell Cycle 
The cell cycle, or cell-division cycle, is the series of events that takes place in a cell 
leading to its division and duplication (replication). In cells without a nucleus 
(prokaryotic), the cell cycle occurs via a process termed binary fission. In cells with 
a nucleus (eukaryotes), the cell cycle can be divided in two brief periods: 
interphase-during which the cell grows, accumulating nutrients needed for mitosis 
and duplicating its DNA-and the mitosis (M) phase, during which the cell splits itself 
into two distinct cells, often called "daughter cells". The cell-division cycle is a vital 
process by which a single-celled fertilized egg develops into a mature organism, as 
well as the process by which hair, skin, blood cells, and some internal organs are 
renewed. The cell cycle consists of four distinct phases: G1 phase, S phase 
(synthesis), G2 phase (collectively known as interphase) and M phase (mitosis). M 
phase is itself composed of two tightly coupled processes: mitosis, in which the 
cell's chromosomes are divided between the two daughter cells, and cytokinesis, in 
which the cell's cytoplasm divides in half forming distinct cells. Activation of each 
phase is dependent on the proper progression and completion of the previous one. 
Cells that have temporarily or reversibly stopped dividing are said to have entered 
a state of quiescence called G0 phase (Figure 5.12). 
 
 
Figure 5.12. The eukaryotic cell cycle is divided into four distinctphases (G1, S, 
G2, M), each of which is regulated by a series of proteins that are attractive targets 
for small molecule cell-cycle inhibitors. 
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5.3.2 Flow cytometry (FCM)  
FCM is a technique for counting and examining microscopic particles, such as cells 
and chromosomes, by suspending them in a stream of fluid and passing them by 
an electronic detection apparatus. It allows simultaneous multiparametric analysis 
of the physical and/or chemical characteristics of up to thousands of particles per 
second. FCM is routinely used in the diagnosis of health disorders, especially blood 
cancers, but has many other applications in both research and clinical practice. 
Fluorescence-activated cell sorting (FACS) is a specialized type of flow cytometry. 
It provides a method for sorting a heterogeneous mixture of biological cells into two 
or more containers, one cell at a time, based upon the specific light scattering and 
fluorescent characteristics of each cell. Two of the most popular flow cytometric 
applications are the measurement of cellular DNA content and the analysis of the 
cell cycle.  
 
5.3.3 Measurement of cellular DNA content and cell cycle by FACS 
The nuclear DNA content of a cell can be quantitatively measured at high speed by 
flowcytometry. Initially, a fluorescent dye that binds stoichiometrically to the DNA is 
added to a suspension of permeabilized single cells or nuclei. The principle is that 
the stained material has incorporated an amount of dye proportional to the amount 
of DNA. The stained material is then measured in the flow cytometer and the 
emitted fluorescent signal yields an electronic pulse with a height (amplitude) 
proportional to the total fluorescence emission from the cell. Thereafter, such 
fluorescence data are considered a measurement of the cellular DNA content. 
Samples should be analyzed at rates below 1000 cells per second in order to yield 
a good signal of discrimination between singlets or doublets. Since the data 
obtained is not a direct measure of cellular DNA content, reference cells with 
various amounts of DNA should be included in order to identify the position of the 
cells with the normal diploid amount of DNA. Some of the common reference cells 
often used for DNA measurements are human leukocytes or red blood cells from 
chicken and trout . Commonly DNA measurements are expressed as a DNA index 
of the ratio of sample DNA peak channel to reference DNA peak channel. In 
addition to determining the relative cellular DNA content, flow cytometry also 
enables the identification of the cell distribution during the various phases of the 
cell cycle. Four distinct phases could be recognized in a proliferating cell 
population: the G1, S (DNA synthesis phase), G2 and M-phase (mitosis). However, 
G2 and M-phase, which both have an identical DNA content could not be 
discriminated based on their differences in DNA content. Diverse software 
containing mathematical models that fit the DNA histogram of a singlet have been 
developed in order to calculate the percentages of cells occupying the different 
phases of the cell cycle. 
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5.3.4 Apoptosis 
Apoptosis is the process of programmed cell death through a tightly controlled 
program that plays important roles in many normal processes, ranging from fetal 
development to adult tissue homeostasis [120]. During apoptosis, the nucleus and 
cytoplasm condense to produce membrane-bound apoptotic bodies that are 
phagocytosed by macrophages or adjacent cells. A tumor is a disease state 
characterized by uncontrolled proliferation and a loss of apoptosis. Compounds 
that block or suppress the proliferation of tumor cells by inducing apoptosis are 
considered to have potential as antitumor agents [121]. 
 
5.3.5 MCF-7 cell cycle analysing in treatment with iPA 
To study the mechanism of antiproliferative activity by iPA in detail, we analyzed 
the effects of Ipa treatment on cell cycle distributions of MCF-7 cells. Cells were 
treated with various concentration of iPA for 72 h and subject to FACS analysis 
after PI staining of the chromosomal DNA.  
 
 
 
 
Figure 5.13. Flow cytometric analysis of MCF-7 cells. Values are expressed  as 
percentage of the cell population in the G1, S, and G1/M phase of cell cycle.  
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In histograms of FACS analysis, untreated proliferative MCF-7 cells showed cell 
cycle distributions of 25.99% in G1/G0, 11.14% in S, 52.38% in G2/M, and 12.27% 
in sub G1/G0 phase. At  all concentrations, iPA  leads to decrease in the 
percentage of cells in G2/M phase, which and increase percentage of cells in sub 
G1/G0 phase. At 10µM of iPA, these populations reached 23.95% for G2/M and 
40.66 µM for sub G1/G0 phase (Figure. 5.13 and 5.14). These data indicates that 
iPA has an activity to arrest MCF-7 cell growth in G2/M. 
In addition, cell cycle analysis was performed, and it was found that the drug 
addition did not good change the duration of the cell cycle in S and G0/G1 phases 
but as shown in Figure. 5.13 and 5.14 in treatment of MCF-7 cells to 10µM   of iPA 
was found to induce apoptosis approximately 40.66 %.  
 
 
 
Figure 5.14. Cell cycle analysis of MCF-7 cells treated with 0, 1, 5, 10µM of iPA. 
 
5.3.6 HCT-15 cell cycle analysing in treatment with KR 
To study the mechanism of antiproliferative activity by KR in detail, we analyzed 
the effects of Ipa treatment on cell cycle distributions of HCT-15 cells. Cells were 
treated with various concentration of KR for 72 h and subject to FACS analysis 
after PI staining of the chromosomal DNA. In histograms of FACS analysis, 
untreated proliferative HCT-15 cells showed cell cycle distributions of 68.25% in 
G1/G0, 8.68% in S, 14.54% in G2/M, and 4.11% in sub G1/G0 phase. At  the 
concentration of 5 µM, KR leads to decrease in the percentage of cells in G0/G1 
phase, which and increase percentage of cells in S and G2/M phase. At 5µM of KR, 
these populations reached 33.3% for G2/M and 16.65% for S phase and 47.78% 
for 33.3% for G0/G1(Figure. 5.15. and 5.16.). These data indicates that KR has an 
activity to arrest HCT-15 cell growth in G2/M and G0/G1. In addition, cell cycle 
analysis was performed, and it was found that the drug addition did not change the 
duration of the cell cycle in sub G1/G0 phase as shown in Figure. 5.15 and 5.16. 
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Figure 5.15. Flow cytometric analysis of HCT-15 cells. Values are expressed  as 
percentage of the cell population in the G1, S, and G1/M phase of cell cycle.  
 
 
Figure 5.16. Cell cycle analysis of HCT-15 cells treated with 5 µM of KR. 
 
5.4 DNA binding study iPA by UV spectroscopy 
The UV spectra have been recorded for a constant DNA concentration in different 
[DNA]/[compound] mixing ratios (r). UV spectra of DNA in the presence of a 
complex derived for diverse (r) values are shown representatively for iPA in Figure 
5.17. The intrinsic binding constants, K, of the compounds with DNA have been 
determined using the UV spectra of the compounds recorded for a constant 
concentration in the absence or presence of DNA for diverse (r) values. The 
ntensity at λmax= 259 nm remains almost stable and is accompanied by a red-shift 
of the λmax up to 269 nm for all complexes (Figure 5.17A).  
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Figure 5.17. (A) UV-vis absorbance spectra (259 nm) of DNA in the presence of  
iPA. (B) The plot of 1/(A-A0) vs 1/L for DNA and iPA complexes at different drug 
concentrations. 
 
The observed a red-shift of 10 nm from λmax = 258 nm up to 269 nm is an evidence 
of the stabilization of the DNA duplex [122,123]. The absorption intensity at 258 nm 
is increased due to the fact that the purine and pyrimidine DNA–bases are exposed 
because of the binding of the compound to DNA. These characteristics can be 
attributed to an interaction [124] having caused the changes of the conformation of 
DNA [125], while the existence of the intercalative binding mode may not be ruled 
out [126,127]. The observed hyperchromic effect suggests binding to DNA 
attributed either to external contact (electrostatic or groove binding) or to the fact 
that  iPA could uncoil the helix structure of DNA resulting in a destabilization of the 
DNA duplex [128]. Any interaction between each compound and FS-DNA could 
perturb the intraligand centred spectral transition bands of the compound [129]. 
High significant changes are observed in the position of the п-п* transition bands of 
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the iPA upon addition of DNA. Our data show that 1/[complexed ligand] almost 
proportionally increases as a function of 1/[free ligand] (Figure 5.17B.). Therefore, 
an overall binding constant KiPA–DNA=4.4 x  10
3 M-1 can be estimated for iPA–DNA.  
 
5.5 BSA binding study iPA by UV spectroscopy 
To explore the structural change of BSA by addition of iPA, we measured UV–vis 
spectra (Figure 5.18) of BSA with various amounts of iPA. BSA free has strong 
absorbance with a peak at about 278  nm and According to literature [130] the 
absorption peak at 278 nm appears due to phonyl group of tryptophan residues 
(Trp) and tyrosines.  It can be seen that all the peaks in different iPA 
concentrations do show considerable shift, however, the intensity is strongly 
dependant on the iPA concentrations.  
 
 
Figure 5.18.   UV–vis absorption spectra of BSA in the presence of 5 at range of 
240 nm to 360 nm. The plot of 1/(A-A0) vs 1/L for BSA-protein and 5 complexes 
where A0 is the initial protein absorption band (278 nm) and A is the recorded 
absorption at different drug concentrations (L). 
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The UV–vis spectra of BSA at different contents of iPA show that in the visible 
region, the absorption peaks of these solutions showed moderate shifts towards 
longer wavelength with red shift indicating that with the addition of iPA, the peptide 
strands of BSA molecules extended more and the hydrophobicity was increased 
[131]. The spectroscopic results showed that iPA is located along the polypeptide 
chains with overall affinity constant of KiPA=4.9 x 10
4 M-1 and these spectral 
changes were caused by compound–BSA complex formation, in which compound 
iPA was strongly bound at the hydrophobic positions of the BSA supported by the 
hydrophobic interaction. It was obvious that hydrophobic substituents of compound 
iPA proved to be a key structural unit for their binding abilities to BSA, which might 
provide some suggestions on the understanding of their exclusive antitumor 
selectivity against HCT-15 and MCF-7 cell lines.  
 
5.6 Binding Constant study of 5 with DNA and BSA 
The ligand–Macromolecules (DNA& BSA) binding constants were determined 
using UV absorption spectroscopy [132,133].  The calculation of the overall binding 
constants was carried out on the basis of UV absorption as  reported [134]. The 
equilibrium for ligands and Macromolecules complex can be described as follows:  
 
 [Macromolecules + Ligand] ↔ [Macromolecules - Ligand]Kligand 
K ligand = [Macromolecules -
 Ligand]/ [Macromolecules][Ligand] 
 
The double reciprocal plot of 1/[A -A0] vs 1/[ligand] is linear and the association 
binding constant (K) is calculated from the ratio of the intercept on the vertical 
coordinate axis to the slope [135,136]. Our data of 1/[ligand complexed] almost 
proportionally increased as a function of 1/[free ligand] and thus the overall binding 
constants are estimated to be KiPA=4.9 x 10
4 M-1 for iPA–BSA and KiPA–DNA =4.4 x  
103 M-1 for iPA–DNA (Figure 5.17B and Figure 5.18B). 
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6. Conclusions 
Antiproliferation activity of iPA and KR against human breast cancer MCF-7 and 
colon cancer HCT-15 cells were investigated by SRB assay and our results 
showed that the cytotoxic effect of iPA and KR on cancer cells. iPA and KR caused 
dose dependent cell death in MCF-7 and HCT-15. We have calculated an IC50 of 
12.2 μmol/L for  iPA against MCF-7 and IC50 of 15 μmol/L for  KR against MCF-7. 
Cell shape and morphology of treated and untreated (control) cells were viewed 
using an inverted phase-contrast microscope model Zeiss and photographed using 
a Nikon camera attached to the microscope. Control group showed regular 
polygonal shape and cell antennas were short.  The cell morphology of treated 
cells was affected by iPA and KR treatment and loss of adhesion, rounding, cell 
shrinkage and detachment from the substratum. The MCF-7 cell cycle analysis by 
flow cytometry showed that there was a prominent increase in the amount of sub-
G1/G0 phase by iPA treatment. In histograms of FACS analysis, untreated 
proliferative MCF-7 cells showed cell cycle distributions of 25.99% in G1/G0, 
11.14% in S, 52.38% in G2/M, and 12.27% in sub G1/G0 phase. At  all 
concentrations, iPA  leads to decrease in the percentage of cells in G2/M phase, 
which and increase percentage of cells in sub G1/G0 phase. At 10µM of iPA, these 
populations reached 23.95% for G2/M and 40.66 µM for sub G1/G0 phase. These 
data indicates that iPA has an activity to arrest MCF-7 cell growth in G2/M and this 
increase of hypoploid DNA is an indication of the inhibition of cell growth through a 
mechanism of apoptosis that has been suggested also for other cell lines. Also 
untreated proliferative HCT-15 cells showed cell cycle distributions of 68.25% in 
G1/G0, 8.68% in S, 14.54% in G2/M, and 4.11% in sub G1/G0 phase. At  the 
concentration of 5 µM, KR leads to decrease in the percentage of cells in G0/G1 
phase, which and increase percentage of cells in S and G2/M phase. At 5µM of KR, 
these populations reached 33.3% for G2/M and 16.65% for S phase and 47.78% 
for 33.3% for G0/G1.These data indicates that KR has an activity to arrest HCT-15 
cell growth in G2/M and G0/G1. On the other hand, the connection between DNA 
damage and apoptosis is supported by a large body of literature [110,111]. At 
present, no clear evidence of iPA-induced DNA damage has been demonstrated, 
except the DNA-fragmentation reported by Laezza et al, that is related to iPA 
treatment of  DLD1 colon cancer cells [46,47]. Our result from structural analysis 
showed interaction of iPA with DNA and the binding constant value (KiPA–DNA=4.4 x 
103 M-1) together with the shift of UV-vis absorbance suggest that iPA interacts at 
DNA surface [137]. Further research is required in order to demonstrate that this 
surface-binding effect may be related to DNA damage in MCF-7 cells. Additionally, 
we present results obtained from the interaction of iPA and BSA since protein–drug 
binding greatly influences absorption, distribution, metabolism, and excretion 
properties of typical drugs, studies on the protein–drug binding are important for 
the elucidation of the reaction mechanisms, providing a pathway to the 
Conclusions 
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pharmacokinetics and pharmacodynamic mechanisms of these substances in 
various tissues. The spectroscopic results showed that iPA is located along the 
polypeptide chains with overall affinity constant of KiPA-BSA= 4.9 x 10
4 M-1 and these 
spectral changes were caused by compound–BSA complex formation, in which 
compound iPA was strongly bound at the hydrophobic positions of the BSA 
supported by the hydrophobic interaction. It was obvious that hydrophobic 
substituents of compound iPA proved to be a key structural unit for their binding 
abilities to BSA, which might provide some suggestions on the understanding of 
their exclusive antitumor selectivity against HCT-15 and MCF-7 cell lines.  
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